A compound and its application

By extracting Meglutol-derived compounds from yam roots, a pharmaceutical composition for inhibiting the expression of inflammatory factors was prepared, which solved the problem of side effects of existing anti-inflammatory drugs and achieved safe and efficient anti-inflammatory effects, especially in the treatment of arthritis. It shows good economic benefits and application prospects in other inflammatory diseases.

CN118652245BActive Publication Date: 2024-11-12BEIJING CHILDRENS HOSPITAL AFFILIATED TO CAPITAL MEDICAL UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411147579.4
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-08-21
Publication Date
2024-11-12
Estimated Expiration
2044-08-21

AI Technical Summary

Technical Problem

Existing anti-inflammatory drugs have side effects, especially non-steroidal anti-inflammatory drugs that cause serious harm to human health and lack safe and efficient natural anti-inflammatory drugs.

Method used

Extract a Meglutol-derived compound from the root of the bean, and its structure is shown in formula (I), and is used to prepare pharmaceutical compositions to relieve inflammatory states or diseases, including arthritis, etc., by inhibiting inflammatory factors such as COX2, PGE2, iNOS, Expression of TNFα, IL6, IL8.

Benefits of technology

This compound shows good anti-inflammatory effects, has the potential to develop into anti-inflammatory drugs, economic benefits and application prospects, and can effectively reduce the expression of inflammatory factors and reduce the inflammatory state.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118652245B_ABST
    Figure CN118652245B_ABST
Patent Text Reader

Abstract

The present invention discloses a compound and its application. The present invention discloses a class of meglutol derivative compounds discovered from Sophora flavescens, and there is no relevant report on the structure and activity of the compounds in the prior art. Further research has found that the compounds have good anti-inflammatory effects, have the potential to be developed into anti-inflammatory drugs, and have good economic benefits and application prospects.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of biomedicine, and specifically relates to a compound and application thereof. Background Art

[0002] The search for drugs with potential clinical application value from plants or traditional Chinese medicine is gradually gaining attention from researchers. Studies have found that drugs extracted from plants have broad prospects due to their low toxicity and side effects.

[0003] Inflammation is a defensive response of the body to external irritants and injuries, manifested as redness, swelling, heat, pain and dysfunction. Short-term inflammation helps to remove inflammatory substances and promote recovery, while excessive or long-term inflammation can lead to diseases such as cancer, arthritis, and sepsis, which seriously threaten human health. The treatment drugs for inflammatory diseases mainly include steroids and non-steroidal anti-inflammatory drugs. These drugs currently used have more or less side effects. For example, non-steroidal anti-inflammatory drugs cause changes in the hematopoietic system, cardiovascular damage, asthma, etc., which have caused serious harm to human health.

[0004] Therefore, finding safe and effective anti-inflammatory drugs from natural plants is of great significance to protecting human life and health. Summary of the invention

[0005] To make up for the deficiencies of the prior art, the present invention provides a compound and application thereof.

[0006] To achieve the above object, the present invention adopts the following technical solution:

[0007] The first aspect of the present invention provides a compound, the structure of which is shown in formula (I):

[0008] .

[0009] Furthermore, the compound also includes stereoisomers or pharmaceutically acceptable salts of the compound represented by formula (I).

[0010] Furthermore, the pharmaceutically acceptable salts include salts formed by the reaction of the compound or its stereoisomers with inorganic bases / acids or organic bases / acids.

[0011] The second aspect of the present invention provides a pharmaceutical composition, which comprises the compound described in the first aspect of the present invention.

[0012] Furthermore, the pharmaceutical composition also includes a pharmaceutically acceptable carrier.

[0013] Furthermore, the dosage form of the pharmaceutical composition includes tablets, capsules, granules, oral liquids, buccal tablets, suspensions, suppositories, injections, powder injections, pills, sustained-release preparations or controlled-release preparations.

[0014] The third aspect of the present invention provides use of the compound described in the first aspect of the present invention in preparing a pharmaceutical composition.

[0015] Furthermore, the pharmaceutical composition is used to alleviate inflammatory conditions or diseases.

[0016] Furthermore, the inflammatory diseases include arthritis, tracheitis, dermatitis, and enteritis.

[0017] Furthermore, the inflammatory disease is selected from arthritis.

[0018] Furthermore, the arthritis includes osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, and gouty arthritis.

[0019] Furthermore, the arthritis is selected from osteoarthritis.

[0020] The fourth aspect of the present invention provides use of the compound described in the first aspect of the present invention in the preparation of a product for inhibiting inflammatory factors.

[0021] Furthermore, the inflammatory factors include one or more of COX2, PGE2, iNOS, TNFα, IL6, IL8, IL26, IL22, IL20, IL10, IL38, IL33, and IL18.

[0022] Furthermore, the inflammatory factors include one or more of COX2, PGE2, iNOS, TNFα, IL6, and IL8.

[0023] Advantages and beneficial effects of the present invention:

[0024] The present application discloses a class of Meglutol derivative compounds discovered from Sophora flavescens, whose structures and activities are not reported in the prior art. Further research has found that the compound has good anti-inflammatory effects, has the potential to be developed into anti-inflammatory drugs, and has good economic benefits and application prospects. BRIEF DESCRIPTION OF THE DRAWINGS

[0025] Figure 1 is the graph showing the inhibition of COX2, PGE2 and iNOS protein expression by compound 15;

[0026] Figure 2 Compound 15 reduces the expression levels of TNFα, IL6 and IL8. DETAILED DESCRIPTION

[0027] The definitions of some terms used in this specification are provided below. Unless otherwise defined, all technical and scientific terms used herein generally have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.

[0028] The present invention provides a compound, the structure of which is shown in formula (I).

[0029] The compound also includes stereoisomers or pharmaceutically acceptable salts of the compound represented by formula (I).

[0030] In one embodiment, stereoisomers refer to isomers of compounds with the same structural formula that are caused by different stereo configurations of atoms or atomic groups therein, including optical isomers, geometric isomers, and rotational isomers.

[0031] In one embodiment, the above formula (I) does not precisely define the stereostructure of a certain position of the compound. The present application includes all stereoisomers of the compound represented by formula (I) and pharmaceutically acceptable salts thereof. Furthermore, mixtures of stereoisomers and isolated specific stereoisomers are also included in the present application. In the synthetic process for preparing such compounds, or in the process of racemization or epimerization known to those skilled in the art, the product obtained may be a mixture of stereoisomers. When the compound represented by formula (I) exists as tautomers, unless otherwise stated, the present application includes any possible tautomers and pharmaceutically acceptable salts thereof, and mixtures thereof.

[0032] In one embodiment, the prodrug of the compound is included in the protection scope of the present application. Generally, the prodrug refers to a functional derivative that is easily converted into the desired compound in vivo. For example, any pharmaceutically acceptable salt, ester, salt of an ester or other derivative of the compound of the present application, which can directly or indirectly provide the compound of the present application or its pharmaceutically active metabolite or residue after administration to a receptor. Particularly preferred derivatives or prodrugs are those compounds that can increase the bioavailability of the compound of the present application when administered to a patient (for example, can make the orally administered compound more easily absorbed into the blood), or those compounds that promote the delivery of the parent compound to biological organs or sites of action (such as joints).

[0033] In one embodiment, the pharmaceutically acceptable salts include pharmaceutically acceptable salts of the compound represented by formula (I) and pharmaceutically acceptable salts of stereoisomers of the compound represented by formula (I).

[0034] In one embodiment, pharmaceutically acceptable salts refer to salts that retain the biological effectiveness and properties of the compounds of the present application and are generally biologically or otherwise desirable, especially salts prepared from pharmaceutically acceptable non-toxic bases or acids.

[0035] In one embodiment, when the compound provided herein is an acid, it can be derived from a pharmaceutically acceptable non-toxic base, including inorganic bases and organic bases. Salts derived from inorganic bases include salts of aluminum, ammonium, calcium, copper (high and low valence), ferric iron, ferrous iron, lithium, magnesium, manganese (high and low valence), potassium, sodium, zinc and the like. Pharmaceutically acceptable non-toxic organic bases that can be derived into salts include primary amines, secondary amines and tertiary amines, and also include cyclic amines and amines containing substituents, such as naturally occurring and synthetic amines containing substituents. Other pharmaceutically acceptable non-toxic organic bases capable of forming salts include ion exchange resins and arginine, betaine, caffeine, choline, N', N'-dibenzylethylenediamine, diethylamine, 2-diethylaminoethanol, 2-dimethylaminoethanol, ethanolamine, ethylenediamine, N-ethylmorpholine, N-ethylpiperidine, reduced glucosamine, glucosamine, histidine, hydramine, isopropylamine, lysine, methylglucamine, morpholine, piperazine, piperidine, polyamine resins, procaine, purine, theobromine, triethylamine, trimethylamine, tripropylamine, tromethamine, and the like.

[0036] In one embodiment, when the compound provided by the present application is a base, it can be from pharmaceutically acceptable nontoxic acid, including inorganic acid and organic acid. Such acid includes inorganic acid and organic acid, for example, acetic acid, benzenesulfonic acid, benzoic acid, camphorsulfonic acid, citric acid, ethanesulfonic acid, formic acid, fumaric acid, gluconic acid, glutamic acid, hydrobromic acid, hydrochloric acid, isethionic acid, lactic acid, maleic acid, malic acid, mandelic acid, methanesulfonic acid, mucic acid, nitric acid, pamoic acid, pantothenic acid, phosphoric acid, succinic acid, sulfuric acid, tartaric acid and p-toluenesulfonic acid etc. Inorganic acid includes hydrochloric acid, hydrobromic acid, sulfuric acid or phosphoric acid etc., and organic acid includes citric acid, lactic acid, malic acid, gluconic acid, tartaric acid, adipic acid, acetic acid, succinic acid, fumaric acid, aseptic acid, itaconic acid, methanesulfonic acid or benzenesulfonic acid etc.

[0037] The present invention provides a pharmaceutical composition, which comprises the above compound.

[0038] In one embodiment, a composition refers to a product comprising a specified amount of each specified component, and any product produced directly or indirectly by a combination of specified amounts of each specified component. Therefore, pharmaceutical compositions containing the compounds of the present application as active ingredients and methods for preparing the compounds of the present application are also part of the present application. In addition, some crystalline forms of the compounds may exist in polymorphic forms, and such polymorphic forms are included in the present application. In addition, some compounds may form solvates with water (i.e., hydrates) or common organic solvents, and such solvates also fall within the scope of the present application.

[0039] In one embodiment, the pharmaceutical composition of the present application includes a pharmaceutically acceptable carrier and a compound of formula (I) or its stereoisomers, tautomers, polymorphs, solvates, pharmaceutically acceptable salts thereof, or prodrugs thereof. The combination of the compound of formula (I) or its pharmaceutically acceptable salts with one or more other therapeutically active compounds is also included in the pharmaceutical composition of the present application.

[0040] In one embodiment, according to conventional drug mixing technology, the compound shown in formula (I) of the present application, or a drug precursor, or a metabolite, or a pharmaceutically acceptable salt, can be used as an active ingredient and mixed with a pharmaceutically acceptable carrier to form a pharmaceutical composition. The pharmaceutically acceptable carrier can take a variety of forms, depending on the desired mode of administration, for example, oral or injection (including intravenous injection). Therefore, the pharmaceutical composition of the present application can be a separate unit suitable for oral administration, such as a capsule, cachet or tablet containing a predetermined dose of the active component. Further, the pharmaceutical composition of the present application can be in the form of granules, oral liquids, buccal tablets, suspensions, suppositories, injections, powder injections, dripping pills, and sustained-release agents. In addition, in addition to the common dosage forms mentioned above, the compound shown in formula (I) or its pharmaceutically acceptable salt can also be administered by controlled release and / or delivery devices. The pharmaceutical composition of the present application can be prepared by any pharmaceutical method. Generally, this method includes the step of associating the active component with a carrier constituting one or more essential components. Generally, the pharmaceutical composition is prepared by uniformly and intimately mixing the active ingredient with a liquid carrier or a finely divided solid carrier or a mixture of the two. In addition, the product can be conveniently prepared into a desired appearance.

[0041] In one embodiment, pharmaceutically acceptable carriers include any solvents, dispersion media, coatings, surfactants, antioxidants, preservatives (e.g., antibacterial agents, antifungal agents), isotonic agents, absorption delaying agents, salts, preservatives, drug stabilizers, binders, excipients, disintegrants, lubricants, sweeteners, flavoring agents, dyes, etc. and combinations thereof, as known to those skilled in the art (see, e.g., Remington: The Science and Practice of Pharmacy, 22nd Edition). In addition to any conventional carriers that are incompatible with the active ingredient, their use in treatment or pharmaceutical compositions is also contemplated.

[0042] Specifically, the pharmaceutically acceptable carrier used in the present application can be, for example, a solid carrier, a liquid carrier or a gas carrier. Solid carriers include, but are not limited to, lactose, gypsum powder, sucrose, talc, gelatin, agar, pectin, gum arabic, magnesium stearate, stearic acid. Liquid carriers include, but are not limited to, syrup, peanut oil, olive oil and water. Gas carriers include, but are not limited to, carbon dioxide and nitrogen. When preparing oral pharmaceutical preparations, any pharmaceutically convenient medium can be used. For example, water, ethylene glycol, oils, alcohols, flavor enhancers, preservatives, colorants, etc. can be used for oral liquid preparations such as suspensions, elixirs and solutions; and carriers such as starches, sugars, microcrystalline cellulose, diluents, granulating agents, lubricants, adhesives, disintegrants, etc. can be used for oral solid preparations such as powders, capsules and tablets. Considering the ease of administration, tablets and capsules are preferred for oral preparations, and solid pharmaceutical carriers are used here. Optionally, tablet coating can use standard aqueous preparation or non-aqueous preparation technology.

[0043] In one embodiment, tablets containing the compounds or pharmaceutical compositions of the present invention may be formed by compression or molding, and may optionally be made into tablets together with one or more auxiliary components or adjuvants. The active ingredient is mixed with a binder, lubricant, inert diluent, surfactant or dispersant in a free-flowing form such as a powder or granule, and compressed tablets may be obtained by compression in a suitable machine. The powdered compound or pharmaceutical composition is soaked with an inert liquid diluent, and then a molded tablet may be obtained by molding in a suitable machine. The tablet may be film-coated or enteric-coated according to methods known in the art.

[0044] In one embodiment, the pharmaceutical composition in the present application can be an aqueous isotonic solution or suspension for some injectable compositions, and suppositories are advantageously prepared by fat emulsions or suspensoids. The compositions can be sterilized and / or contain adjuvants, such as preservatives, stabilizers, wetting agents or emulsifiers, solution promoters, salts and / or buffers for regulating osmotic pressure. In addition, they may also contain other therapeutically valuable substances. The compositions are prepared according to conventional mixing, granulation or coating methods, respectively.

[0045] In one embodiment, the pharmaceutical composition in the present application can be a suitable composition for transdermal administration, comprising an effective amount of the compound of the present application and a suitable carrier. Suitable carriers for transdermal delivery include absorbable pharmacologically acceptable solvents to help pass through the host skin. For example, the transdermal device is in the form of a bandage, which includes a backing member, a reservoir containing the compound and optionally a carrier, optionally a rate-controlling barrier to deliver the compound to the host skin at a controlled and predetermined rate over a long period of time, and a means for fixing the device to the skin.

[0046] In one embodiment, the pharmaceutical composition will change according to the desired effect. Therefore, the optimal content of the pharmaceutical composition of the present application can be easily determined by those skilled in the art, and can be adjusted according to the following various factors: the type and severity of the disease, the content of other components contained in the pharmaceutical composition, the type of preparation, the patient's age, body weight, general health, sex and diet, application time, route of administration, the secretion rate of the drug, the duration of treatment and the drug used simultaneously. The amount of the pharmaceutical composition should be determined considering the factors, and it can be applied once a day or in several portions. However, it should be understood that the actual dosage of the active ingredient should be determined considering various relevant factors, including the disease treated, the severity of the disease, the route of administration and the patient's weight, age and sex. Therefore, dosage does not limit the scope of the present invention in any way.

[0047] The invention will be further described below in conjunction with specific examples. It should be understood that the specific embodiments described herein are presented by way of example and are not intended to limit the invention. The main features of the invention may be used in a variety of embodiments without departing from the scope of the invention.

[0048] Example 1 Preparation of Meglutol Derivatives from Radix Sophorae Tonkinensis

[0049] Sophora flavescens (50 kg) was crushed and refluxed with distilled water for 3 times, each time for 2 h. The extract was concentrated and eluted with ethanol (0–95%) on a macroporous resin column. The 30% ethanol elution fraction was concentrated and eluted with ethanol (0–75%) on an MCI column. The 10% and 20% ethanol fractions were eluted with a gradient of chloroform-methanol (99:1–1:1) on a silica gel column (60–100 mesh) to obtain Fr.1–41 and Fr.G-1–32. Fr.18–24 and Fr.G-11–18 were combined and eluted with a Diol Flash column (CHCl3-MeOH, 20:1–2:1) to obtain M7-D1–26.

[0050] M7-D4–6 was selected for preparative HPLC purification. The liquid phase conditions were as follows: (1) chromatographic column: PFP chromatographic column (250×10 mm, 5 μm); (2) mobile phase: water / methanol solution; (3) flow rate: 2.5 mL / min; (5) detection wavelength: 205 nm, to obtain the above-mentioned compound 15 (60% methanol, tR=16.0 min).

[0051] The structures of the compounds were confirmed by UV, IR, NMR, MS and CD spectroscopic methods.

[0052] The spectral information and NMR signal attribution of the above compounds are as follows:

[0053] Compound 15* (3''R)-7''',3''''-dihydroxy-8''',4''''-dimethoxyisoflavone 6'''''-O-(3''-hydroxy-3''-methylglutarylmethylester)-3''''-O-β-D-pyranoglucoside, whose structure is shown in formula (I)

[0054] .

[0055] Light yellow powder; [ α ] 20 D-18.6 ( c 0.10,MeOH);ECD(MeOH) l max (Δ e ) 224 (-1.86), 298 (-0.19) nm; UV (MeOH) l max (log e ) 203 (4.14), 253 (3.92) nm; IR n max 3362,2921,2850,1731,1596,1515,1454,1269,1076 cm -1 ; 1 H NMR and 13 C NMR see Table 1; (-)-HRESIMS m / z 633.1829[MH] - (calcd for C 30 H 33 O 15 - , 633.1825).

[0056] Table 1 Compound 15 1 H NMR and 13 C NMR (126 MHz) data (CD3OD)

[0057]

[0058] Measured at a 500 MHz or b 400 MHz.

[0059] c,d Interchangeable signals.

[0060] eOverlapped with solvent and read from HSQC or HMBC

[0061] Example 2 Compound 15 inhibits inflammatory response

[0062] 1. Cellular intervention

[0063] Human chondrocyte cell line C28 / I2 (Cell Resource Center, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences) was seeded in six-well plates at 3.5 × 10 5 Cells were cultured at 37°C in an incubator containing 5% CO2. The culture medium was RPMI-1640 (Gibco) with 10% fetal bovine serum (Hyclone). The groups were divided into control group, model group, and compound 15 (2μM, 10μM) group. The corresponding amount of compound 15 was added to the treatment group and incubated for 2h. The same amount of solvent was added to the model group and the control group. Then IL1-β (10ng / ml) was added to the model group and compound 15 (2μM, 10μM) group, respectively, and incubated for 24h. Total RNA and protein were extracted for subsequent experiments.

[0064] 2. Western Blot

[0065] The obtained cells were used to extract total cell protein using high-efficiency RIPA tissue / cell rapid lysis buffer. The protein concentration was determined using a BCA protein quantification kit. The 20 mg / ml BSA standard protein was diluted to 2, 1, 0.5, 0.25, 0.125 and 0.0625 as a standard. In each well of a 96-well plate, 100 μl of the prepared BCA solution was added, 10 μl of sample or standard was added, mixed, incubated at 37°C for 30 min, and the absorbance at 562 nm was detected using an enzyme reader. A standard curve was prepared based on the absorbance, the concentration of each sample was calculated, and the sample was mixed with 5× Loading Buffer and boiled at 98°C for 10 min to denature the protein. The samples were loaded, separated by SDS-PAGE, transferred to PVDF membrane at 100 V, blocked with 5% skim milk at room temperature for 1 h, washed with TBST for 10 min, 3 times, and then added with primary antibodies [GAPDH, COX2, PGE2 and iNOS (1:1000)], and incubated at 4°C overnight. The next day, the membrane was washed in the same way, and the corresponding secondary antibodies (1:2000) were added, incubated at room temperature for 1 h, washed, and ECL developer (1:1) was added, mixed, and exposed with Tanon 5200 chemiluminescence imaging analysis system.

[0066] Protein expression results Figure 1As shown, COX2, PGE2 and iNOS in the model group were significantly increased, indicating that C28 / I2 had an inflammatory reaction and the model was successfully established. In the compound 15 (1.6μM, 8μM) group, COX2, PGE2 and iNOS protein expressions were all reduced, indicating that compound 15 played an anti-inflammatory role.

[0067] 3. Real-time PCR

[0068] Total RNA was extracted from the obtained cells using an RNA rapid extraction kit, and the RNA concentration and purity were determined using a Synergy H1 microplate reader at 260nm / 280nm. The obtained RNA was reverse transcribed into cDNA using a Transgen kit, and then operated according to Yeasen's qPCR kit. GAPDH, TNFα, IL6 and IL8 primers were synthesized by Beijing Ruibo Xingke Biotechnology Co., Ltd. The primer sequences are shown in Table 2. Analytik Jena qTOWER3 fluorescent quantitative gene amplification instrument was used for detection, and melting curve analysis was used to evaluate the reliability of PCR results. The PCR program was: 95℃ 5 min; 95℃ 10 s, 60℃ 30s, 72℃ 10 s, 39 cycles. GAPDH was used as an internal reference, and the expression level of the gene to be tested was expressed as 2-ΔΔCt.

[0069] Table 2 Real-time PCR primer sequences

[0070]

[0071] like Figure 2 As shown in the figure, compared with the control group, the expression levels of TNFα, IL6 and IL8 in the model group were significantly increased, indicating that C28 / I2 had an inflammatory response at this time and the model was successfully established. Compared with the model group, the expression levels of TNFα, IL6 and IL8 in the compound 15 (1.6μM, 8μM) group were significantly reduced, and there was a dose-dependent relationship, indicating that the C28 / I2 inflammatory response was alleviated to a certain extent, and compound 15 had the effect of reducing the C28 / I2 inflammatory response.

[0072] The description of the above embodiments is only used to understand the method and core idea of ​​the present invention. It should be pointed out that, for those skilled in the art, several improvements and modifications can be made to the present invention without departing from the principle of the present invention, and these improvements and modifications will also fall within the scope of protection of the claims of the present invention.

Claims

1. A compound, characterized in that The structure of the compound is shown in formula (I): 。 2. The compound according to claim 1, characterized in that The compound also includes stereoisomers or pharmaceutically acceptable salts of the compound represented by formula (I).

3. The compound according to claim 2, characterized in that The pharmaceutically acceptable salts include salts formed by reacting the compound or its stereoisomers with inorganic bases / acids or organic bases / acids.

4. A pharmaceutical composition, characterized in that The pharmaceutical composition comprises the compound according to any one of claims 1 to 3.

5. The pharmaceutical composition according to claim 4, characterized in that The pharmaceutical composition also includes a pharmaceutically acceptable carrier.

6. The pharmaceutical composition according to claim 5, characterized in that The dosage forms of the pharmaceutical composition include tablets, capsules, granules, oral liquids, buccal tablets, suspensions, suppositories, injections, powder injections, dropping pills, sustained-release preparations or controlled-release preparations.

7. Use of the compound according to any one of claims 1 to 3 in the preparation of a pharmaceutical composition; The pharmaceutical composition is used for alleviating osteoarthritis.

8. Use of the compound according to any one of claims 1 to 3 in the preparation of a product for inhibiting inflammatory factors, wherein the inflammatory factors are selected from one or more of COX2, PGE2, iNOS, TNFα, IL6, and IL8.